Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 13 Stomach Neoplasms 3 Neoplasm Metastasis 3 Carcinoma, Hepatocellular 3 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Unresectable Locally Advanced or Metastatic Solid Tumors 1 Turcot syndrome 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Tertiary Lymphoid Structures 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Osteosarcoma 1 Mesothelioma, Malignant 1 Melanoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Esophageal Squamous Cell Carcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Brain Neoplasms 1

Interventions

Fluorouracil 8 Oxaliplatin 7 Leucovorin 6 Irinotecan 6 Gemcitabine 5 fludarabine 3 aldesleukin 3 Pemetrexed 3 Nivolumab 3 Cyclophosphamide 3 Cetuximab 3 Capecitabine 3 5,10-methylenetetrahydrofolic acid 3 dehydroftorafur 2 cobimetinib 2 Specimen Handling 2 Panitumumab 2 Interleukin-2 2 Docetaxel 2 Bevacizumab 2 130-nm albumin-bound paclitaxel 2 tivozanib 1 sodium propionate 1 rucaparib 1 rilotumumab 1 repotrectinib 1 regorafenib 1 pralsetinib 1 pertuzumab 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Gastrointestinal Neoplasms × regorafenib × Clear all

NCT02386397 2026-03-12

BREGO

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 1/2 Completed

Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡